Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 4
2007 1
2008 1
2011 1
2012 1
2015 1
2016 1
2018 1
2020 2
2021 1
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
Berry C, Pavot V, Anosova NG, Kishko M, Li L, Tibbitts T, Raillard A, Gautheron S, Cummings S, Bangari DS, Kar S, Atyeo C, Deng Y, Alter G, Gutzeit C, Koutsoukos M, Chicz RM, Lecouturier V. Berry C, et al. Among authors: kishko m. Commun Med (Lond). 2023 May 26;3(1):75. doi: 10.1038/s43856-023-00302-z. Commun Med (Lond). 2023. PMID: 37237062 Free PMC article.
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
Kalnin KV, Plitnik T, Kishko M, Huang D, Raillard A, Piolat J, Anosova NG, Tibbitts T, DiNapoli J, Karve S, Goldman R, Gopani H, Dias A, Tran K, Zacharia M, Gu X, Boeglin L, Abysalh J, Vargas J, Beaulieu A, Shah M, Jeannotte T, Gillis K, Chivukula S, Swearingen R, Landolfi V, Fu TM, DeRosa F, Casimiro D. Kalnin KV, et al. Among authors: kishko m. Vaccine. 2022 Feb 23;40(9):1289-1298. doi: 10.1016/j.vaccine.2022.01.021. Epub 2022 Jan 31. Vaccine. 2022. PMID: 35101265 Free PMC article.
Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle.
Rainho-Tomko JN, Pavot V, Kishko M, Swanson K, Edwards D, Yoon H, Lanza L, Alamares-Sapuay J, Osei-Bonsu R, Mundle ST, Murison DA, Gallichan S, Delagrave S, Wei CJ, Zhang L, Nabel GJ. Rainho-Tomko JN, et al. Among authors: kishko m. NPJ Vaccines. 2022 Jun 30;7(1):74. doi: 10.1038/s41541-022-00487-9. NPJ Vaccines. 2022. PMID: 35773301 Free PMC article.
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.
Kalnin KV, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, Anosova NG, Tibbitts T, DiNapoli J, Ulinski G, Piepenhagen P, Cummings SM, Bangari DS, Ryan S, Huang PD, Huleatt J, Vincent D, Fries K, Karve S, Goldman R, Gopani H, Dias A, Tran K, Zacharia M, Gu X, Boeglin L, Abysalh J, Vargas J, Beaulieu A, Shah M, Jeannotte T, Gillis K, Chivukula S, Swearingen R, Landolfi V, Fu TM, DeRosa F, Casimiro D. Kalnin KV, et al. Among authors: kishko m. NPJ Vaccines. 2021 Apr 19;6(1):61. doi: 10.1038/s41541-021-00324-5. NPJ Vaccines. 2021. PMID: 33875658 Free PMC article.
A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain.
Swanson KA, Rainho-Tomko JN, Williams ZP, Lanza L, Peredelchuk M, Kishko M, Pavot V, Alamares-Sapuay J, Adhikarla H, Gupta S, Chivukula S, Gallichan S, Zhang L, Jackson N, Yoon H, Edwards D, Wei CJ, Nabel GJ. Swanson KA, et al. Among authors: kishko m. Sci Immunol. 2020 May 1;5(47):eaba6466. doi: 10.1126/sciimmunol.aba6466. Sci Immunol. 2020. PMID: 32358170
22 results